Company: HRTX
Filing Date: 2025-09-19
Form Type: DEF 14A
Source: 0001193125-25-209064
Chunk: 7

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-19
Form: DEF 14A
Chunk 7
---
 voting instructions to your bank, broker or nominee following the instructions they provide.

If your shares are held by your broker, bank or other agent (that is, in “street name”), you will need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker, bank or other agent to vote your shares. If a beneficial owner of shares held in “street name” does not give instructions to his or her broker, bank or other agent, such nominee has discretionary authority to vote such shares with respect to “routine” matters but does not have discretionary authority to vote such shares with respect to “non-routine” matters. For “non-routine” matters for which a broker, bank or other agent does not have discretionary authority to vote a beneficial owner’s shares, the un-voted shares are generally referred to and counted as “broker non-votes.” The determination of whether a proposal is “routine” or “non-routine” is made pursuant to applicable stock exchange rules.

The approval of the issuance of shares of the Company’s Common Stock upon the conversion of convertible senior unsecured promissory notes due 2031 (“Proposal 1”) and the approval of the issuance of shares of the Company’s Common Stock upon the conversion of the Company’s Series A Convertible Preferred Stock (“Proposal 2”) are considered as “non-routine” matters under applicable rules. We therefore expect broker non-votes to exist in connection with Proposals 1 and 2.

Votes will be counted by the Inspector of Elections appointed for the Special Meeting. Once a quorum is present, a majority of the votes cast at the Special Meeting in person or represented by proxy is required to approve each of

<div align='center'>7</div>

Proposal 1 and Proposal 2. Stockholders who participated in the transactions seeking to be approve at this Special Meeting are entitled to vote the shares of Common Stock held by them, except that they may not vote the shares of Common Stock they received in such transactions. There are no appraisal or dissenter’s rights with respect to the matters to be acted upon at the Special Meeting.

Broker non-votes and abstentions are counted for purposes of determining whether a quorum is present at the Special Meeting. Broker non-votes will have no effect on Proposals 1 and 2.

Abstentions will be counted as votes present and entitled to vote on the proposals considered at the Special Meeting, but will not be considered as a vote cast